{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T08:17:15Z","timestamp":1791274635414,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:00:00Z","timestamp":1639612800000},"content-version":"vor","delay-in-days":15,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Peter Munk Cardiac Centre Innovation Fund"},{"name":"Academic Incentive Fund Grant, Toronto Joint Department of Medical Imaging"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["European J Hybrid Imaging"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To evaluate the diagnostic and prognostic significance of combined cardiac<jats:sup>18<\/jats:sup>F-fluorodeoxyglucose (FDG) PET\/MRI with T1\/T2 mapping in the evaluation of suspected cardiac sarcoidosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients with suspected cardiac sarcoidosis were prospectively enrolled for cardiac<jats:sup>18<\/jats:sup>F-FDG PET\/MRI, including late gadolinium enhancement (LGE) and T1\/T2 mapping with calculation of extracellular volume (ECV). The final diagnosis of cardiac sarcoidosis was established using modified JMHW guidelines. Major adverse cardiac events (MACE) were assessed as a composite of cardiovascular death, ventricular tachyarrhythmia, bradyarrhythmia, cardiac transplantation or heart failure. Statistical analysis included Cox proportional hazard models.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Forty-two patients (53\u2009\u00b1\u200913\u00a0years, 67% male) were evaluated, 13 (31%) with a final diagnosis of cardiac sarcoidosis. Among patients with cardiac sarcoidosis, 100% of patients had at least one abnormality on PET\/MRI: FDG uptake in 69%, LGE in 100%, elevated T1 and ECV in 100%, and elevated T2 in 46%. FDG uptake co-localized with LGE in 69% of patients with cardiac sarcoidosis compared to 24% of those without,<jats:italic>p<\/jats:italic>\u2009=\u20090.014. Diagnostic specificity for cardiac sarcoidosis was highest for FDG uptake (69%), elevated T2 (79%), and FDG uptake co-localizing with LGE (76%). Diagnostic sensitivity was highest for LGE, elevated T1 and ECV (100%). After median follow-up duration of 634\u00a0days, 13 patients experienced MACE. All patients who experienced MACE had LGE, elevated T1 and elevated ECV. FDG uptake (HR 14.7,<jats:italic>p<\/jats:italic>\u2009=\u20090.002), elevated T2 (HR 9.0,<jats:italic>p<\/jats:italic>\u2009=\u20090.002) and native T1 (HR 1.1 per 10\u00a0ms increase,<jats:italic>p<\/jats:italic>\u2009=\u20090.044) were significant predictors of MACE even after adjusting for left ventricular ejection fraction and immune suppression treatment. The presence of FDG uptake co-localizing with LGE had the highest diagnostic performance overall (AUC 0.73) and was the best predictor of MACE based on model goodness of fit (HR 14.9,<jats:italic>p<\/jats:italic>\u2009=\u20090.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Combined cardiac FDG-PET\/MRI with T1\/T2 mapping provides complementary diagnostic information and predicts MACE in patients with suspected cardiac sarcoidosis.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s41824-021-00119-w","type":"journal-article","created":{"date-parts":[[2021,12,16]],"date-time":"2021-12-16T00:03:37Z","timestamp":1639613017000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Combined simultaneous FDG-PET\/MRI with T1 and T2 mapping as an imaging biomarker for the diagnosis and prognosis of suspected cardiac sarcoidosis"],"prefix":"10.1186","volume":"5","author":[{"given":"Edward","family":"Cheung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Aitken","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert M.","family":"Iwanochko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meyer","family":"Balter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ur","family":"Metser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Veit-Haibach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filio","family":"Billia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasbanoo","family":"Moayedi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Ross","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3077-2218","authenticated-orcid":false,"given":"Kate","family":"Hanneman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,16]]},"reference":[{"key":"119_CR1","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s12350-014-9901-9","volume":"21","author":"A Ahmadian","year":"2014","unstructured":"Ahmadian A, Brogan A, Berman J, Sverdlov AL, Mercier G, Mazzini M et al (2014) Quantitative interpretation of FDG PET\/CT with myocardial perfusion imaging increases diagnostic information in the evaluation of cardiac sarcoidosis. J Nucl Cardiol 21:925\u2013939","journal-title":"J Nucl Cardiol"},{"key":"119_CR2","first-page":"e210","volume":"138","author":"SM Al-Khatib","year":"2018","unstructured":"Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB et al (2018) 2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Circulation 138:e210\u2013e271","journal-title":"Circulation"},{"key":"119_CR3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jacc.2016.03.605","volume":"68","author":"DH Birnie","year":"2016","unstructured":"Birnie DH, Nery PB, Ha AC, Beanlands RSB (2016) Cardiac sarcoidosis. J Am Coll Cardiol 68:411\u2013421","journal-title":"J Am Coll Cardiol"},{"key":"119_CR4","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.jacc.2013.09.022","volume":"63","author":"R Blankstein","year":"2014","unstructured":"Blankstein R, Osborne M, Naya M, Waller A, Kim CK, Murthy VL et al (2014) Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol 63:329\u2013336","journal-title":"J Am Coll Cardiol"},{"key":"119_CR5","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1161\/hc0402.102975","volume":"105","author":"MD Cerqueira","year":"2002","unstructured":"Cerqueira MD, Weissman NJ, Dilsizian V, Jacobs AK, Kaul S, Laskey WK et al (2002) Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association. Circulation 105:539\u201342","journal-title":"Circulation"},{"key":"119_CR6","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1007\/s11886-019-1158-0","volume":"21","author":"W Chen","year":"2019","unstructured":"Chen W, Jeudy J (2019) Assessment of myocarditis: cardiac MR, PET\/CT, or PET\/MR? Curr Cardiol Rep 21:76","journal-title":"Curr Cardiol Rep"},{"key":"119_CR7","doi-asserted-by":"publisher","first-page":"e190140","DOI":"10.1148\/ryct.2020190140","volume":"2","author":"RA Coulden","year":"2020","unstructured":"Coulden RA, Sonnex EP, Abele JT, Crean AM (2020) Utility of FDG PET and Cardiac MRI in Diagnosis and Monitoring of Immunosuppressive Treatment in Cardiac Sarcoidosis. Radiology Cardiothoracic Imaging. 2:e190140","journal-title":"Radiology Cardiothoracic Imaging."},{"key":"119_CR8","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1148\/rg.291085052","volume":"29","author":"KW Cummings","year":"2009","unstructured":"Cummings KW, Bhalla S, Javidan-Nejad C, Bierhals AJ, Gutierrez FR, Woodard PK (2009) A pattern-based approach to assessment of delayed enhancement in nonischemic cardiomyopathy at MR imaging. Radiographics 29:89\u2013103","journal-title":"Radiographics"},{"key":"119_CR9","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1016\/j.jcmg.2017.02.021","volume":"11","author":"MR Dweck","year":"2017","unstructured":"Dweck MR, Abgral R, Trivieri MG, Robson PM, Karakatsanis N, Mani V et al (2017) Hybrid magnetic resonance imaging and positron emission tomography with fluorodeoxyglucose to diagnose active cardiac sarcoidosis. JACC Cardiovasc Imaging. 11:94","journal-title":"JACC Cardiovasc Imaging."},{"key":"119_CR10","doi-asserted-by":"publisher","first-page":"3158","DOI":"10.1016\/j.jacc.2018.09.072","volume":"72","author":"VM Ferreira","year":"2018","unstructured":"Ferreira VM, Schulz-Menger J, Holmvang G, Kramer CM, Carbone I, Sechtem U et al (2018) Cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol 72:3158\u20133176","journal-title":"J Am Coll Cardiol"},{"key":"119_CR11","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.1007\/s00330-020-06765-1","volume":"30","author":"L Flam\u00e9e","year":"2020","unstructured":"Flam\u00e9e L, Symons R, Degtiarova G, Dresselaers T, Gheysens O, Wuyts W et al (2020) Prognostic value of cardiovascular magnetic resonance in patients with biopsy-proven systemic sarcoidosis. Eur Radiol 30:3702\u20133710","journal-title":"Eur Radiol"},{"key":"119_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41572-019-0096-x","volume":"5","author":"J Grunewald","year":"2019","unstructured":"Grunewald J, Grutters JC, Arkema EV, Saketkoo LA, Moller DR, M\u00fcller-Quernheim J (2019) Sarcoidosis. Nat Rev Disease Primers 5:45","journal-title":"Nat Rev Disease Primers"},{"key":"119_CR13","doi-asserted-by":"publisher","first-page":"e200347","DOI":"10.1148\/ryct.2020200347","volume":"2","author":"M Gutberlet","year":"2020","unstructured":"Gutberlet M (2020) Cardiac MRI and FDG PET in Cardiac Sarcoidosis: Competitors or Collaborators? Radiol Cardiothorac Imaging. 2:e200347","journal-title":"Radiol Cardiothorac Imaging."},{"key":"119_CR14","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1097\/RLU.0000000000001669","volume":"42","author":"K Hanneman","year":"2017","unstructured":"Hanneman K, Kadoch M, Guo HH, Jamali M, Quon A, Iagaru A et al (2017) Initial experience with simultaneous 18F-FDG PET\/MRI in the evaluation of cardiac sarcoidosis and myocarditis. Clin Nucl Med 42:e328\u2013e334","journal-title":"Clin Nucl Med"},{"key":"119_CR15","doi-asserted-by":"crossref","first-page":"e005001","DOI":"10.1161\/CIRCIMAGING.116.005001","volume":"9","author":"E Hulten","year":"2016","unstructured":"Hulten E, Agarwal V, Cahill M, Cole G, Vita T, Parrish S et al (2016) Presence of late gadolinium enhancement by cardiac magnetic resonance among patients with suspected cardiac sarcoidosis is associated with adverse cardiovascular prognosis: a systematic review and meta-analysis. Circ Cardiovasc Imaging. 9:e005001","journal-title":"Circ Cardiovasc Imaging."},{"key":"119_CR16","first-page":"50","volume":"6","author":"E Hulten","year":"2016","unstructured":"Hulten E, Aslam S, Osborne M, Abbasi S, Bittencourt MS, Blankstein R (2016) Cardiac sarcoidosis\u2014state of the art review. Cardiovasc Diagn Ther 6:50\u201363","journal-title":"Cardiovasc Diagn Ther"},{"key":"119_CR17","doi-asserted-by":"publisher","first-page":"2153","DOI":"10.1056\/NEJMra071714","volume":"357","author":"MC Iannuzzi","year":"2007","unstructured":"Iannuzzi MC, Rybicki BA, Teirstein AS (2007) Sarcoidosis. N Engl J Med 357:2153\u20132165","journal-title":"N Engl J Med"},{"key":"119_CR18","first-page":"89","volume":"27","author":"Japanese Ministry Health and Welfare","year":"2007","unstructured":"Japanese Ministry Health and Welfare (2007) Diagnostic standard and guidelines for sarcoidosis. Jpn J Sarcoidosis Granulomatous Disord 27:89\u2013102","journal-title":"Jpn J Sarcoidosis Granulomatous Disord"},{"key":"119_CR19","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1161\/CIRCEP.114.002145","volume":"8","author":"S Kumar","year":"2015","unstructured":"Kumar S, Barbhaiya C, Nagashima K, Choi E-K, Epstein LM, John RM et al (2015) Ventricular tachycardia in cardiac sarcoidosis. Circ Arrhythm Electrophysiol 8:87\u201393","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"119_CR20","first-page":"1491","volume":"12","author":"X Li","year":"2020","unstructured":"Li X, Rosenkrans ZT, Wang J, Cai W (2020) PET imaging of macrophages in cardiovascular diseases. Am J Transl Res 12:1491\u2013514. https:\/\/pubmed.ncbi.nlm.nih.gov\/32509158\/","journal-title":"Am J Transl Res"},{"key":"119_CR21","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1378\/chest.07-2784","volume":"133","author":"D Mehta","year":"2008","unstructured":"Mehta D, Lubitz SA, Frankel Z, Wisnivesky JP, Einstein AJ, Goldman M et al (2008) Cardiac involvement in patients with sarcoidosis: diagnostic and prognostic value of outpatient testing. Chest 133:1426\u20131435","journal-title":"Chest"},{"key":"119_CR22","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1007\/s00259-011-1832-y","volume":"38","author":"H Ohira","year":"2011","unstructured":"Ohira H, Tsujino I, Yoshinaga K (2011) (1)(8)F-Fluoro-2-deoxyglucose positron emission tomography in cardiac sarcoidosis. Eur J Nucl Med Mol Imaging 38:1773\u20131783","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"119_CR23","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1007\/s12350-016-0658-1","volume":"25","author":"DR Okada","year":"2018","unstructured":"Okada DR, Bravo PE, Vita T, Agarwal V, Osborne MT, Taqueti VR et al (2018) Isolated cardiac sarcoidosis: a focused review of an under-recognized entity. J Nucl Cardiol 25:1136\u20131146","journal-title":"J Nucl Cardiol"},{"key":"119_CR24","first-page":"1989","volume":"45","author":"W Okumura","year":"2004","unstructured":"Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N et al (2004) Usefulness of fasting 18F-FDG PET in identification of cardiac sarcoidosis. J Nucl Med 45:1989\u20131998","journal-title":"J Nucl Med"},{"key":"119_CR25","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1161\/CIRCULATIONAHA.109.851352","volume":"120","author":"MR Patel","year":"2009","unstructured":"Patel MR, Cawley PJ, Heitner JF, Klem I, Parker MA, Jaroudi WA et al (2009) Detection of myocardial damage in patients with sarcoidosis. Circulation 120:1969\u20131977","journal-title":"Circulation"},{"key":"119_CR26","first-page":"167","volume":"119","author":"A Perry","year":"1995","unstructured":"Perry A, Vuitch F (1995) Causes of death in patients with sarcoidosis. A morphologic study of 38 autopsies with clinicopathologic correlations. Arch Pathol Lab Med. 119:167\u201372","journal-title":"Arch Pathol Lab Med."},{"key":"119_CR27","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1148\/radiol.2017162732","volume":"285","author":"VO Puntmann","year":"2017","unstructured":"Puntmann VO, Isted A, Hinojar R, Foote L, Carr-White G, Nagel E (2017) T1 and T2 mapping in recognition of early cardiac involvement in systemic sarcoidosis. Radiology 285:63\u201372","journal-title":"Radiology"},{"key":"119_CR28","doi-asserted-by":"publisher","first-page":"402","DOI":"10.2967\/jnumed.112.105353","volume":"54","author":"C Rischpler","year":"2013","unstructured":"Rischpler C, Nekolla SG, Dregely I, Schwaiger M (2013) Hybrid PET\/MR imaging of the heart: potential, initial experiences, and future prospects. J Nucl Med 54:402\u2013415","journal-title":"J Nucl Med"},{"key":"119_CR29","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12968-018-0443-1","volume":"20","author":"S Robison","year":"2018","unstructured":"Robison S, Karur GR, Wald RM, Thavendiranathan P, Crean AM, Hanneman K (2018) Noninvasive hematocrit assessment for cardiovascular magnetic resonance extracellular volume quantification using a point-of-care device and synthetic derivation. J Cardiovasc Magn Reson 20:19","journal-title":"J Cardiovasc Magn Reson"},{"key":"119_CR30","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1093\/oxfordjournals.aje.a009096","volume":"145","author":"BA Rybicki","year":"1997","unstructured":"Rybicki BA, Major M, Popovich JJ, Maliarik MJ, Iannuzzi MC (1997) Racial differences in sarcoidosis incidence: a 5-year study in a health maintenance organization. Am J Epidemiol 145:234\u2013241","journal-title":"Am J Epidemiol"},{"key":"119_CR40","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1148\/ryct.210252","volume":"3","author":"F Sanchez Tijmes","year":"2021","unstructured":"Sanchez Tijmes F, Thavendiranathan P, Udell JA, Seidman MA, Hanneman K (2021) Cardiac MRI assessment of nonischemic myocardial inflammation: state of the art review and update on myocarditis associated with COVID-19 vaccination. Radiol Cardiothorac Imaging 3:6. https:\/\/doi.org\/10.1148\/ryct.210252","journal-title":"Radiol Cardiothorac Imaging"},{"key":"119_CR31","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12968-020-00610-6","volume":"22","author":"J Schulz-Menger","year":"2020","unstructured":"Schulz-Menger J, Bluemke DA, Bremerich J, Flamm SD, Fogel MA, Friedrich MG et al (2020) Standardized image interpretation and post-processing in cardiovascular magnetic resonance - 2020 update. J Cardiovasc Magn Reson 22:19","journal-title":"J Cardiovasc Magn Reson"},{"key":"119_CR32","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s11886-013-0370-6","volume":"15","author":"H Skali","year":"2013","unstructured":"Skali H, Schulman AR, Dorbala S (2013a) (18)F-FDG PET\/CT for the assessment of myocardial sarcoidosis. Curr Cardiol Rep 15:352\u2013362","journal-title":"Curr Cardiol Rep"},{"key":"119_CR33","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1007\/s11886-013-0370-6","volume":"15","author":"H Skali","year":"2013","unstructured":"Skali H, Schulman AR, Dorbala S (2013b) 18F-FDG PET\/CT for the assessment of myocardial sarcoidosis. Curr Cardiol Rep 15:352\u2013362","journal-title":"Curr Cardiol Rep"},{"key":"119_CR34","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1007\/s00259-020-05066-5","volume":"48","author":"RHJA Slart","year":"2021","unstructured":"Slart RHJA, Glaudemans AWJM, Gheysens O, Lubberink M, Kero T, Dweck MR et al (2021) Procedural recommendations of cardiac PET\/CT imaging: standardization in inflammatory-, infective-, infiltrative-, and innervation (4Is)-related cardiovascular diseases: a joint collaboration of the EACVI and the EANM. Eur J Nucl Med Mol Imaging 48:1016\u20131039","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"119_CR35","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/j.jacc.2005.01.047","volume":"45","author":"J-P Smedema","year":"2005","unstructured":"Smedema J-P, Snoep G, van Kroonenburgh MPG, van Geuns R-J, Dassen WRM, Gorgels APM et al (2005) Evaluation of the accuracy of gadolinium-enhanced cardiovascular magnetic resonance in the diagnosis of cardiac sarcoidosis. J Am Coll Cardiol 45:1683\u20131690","journal-title":"J Am Coll Cardiol"},{"key":"119_CR36","doi-asserted-by":"publisher","first-page":"249","DOI":"10.2214\/ajr.184.1.01840249","volume":"184","author":"O Vignaux","year":"2005","unstructured":"Vignaux O (2005) Cardiac sarcoidosis: spectrum of MRI features. Am J Roentgenol 184:249\u2013254","journal-title":"Am J Roentgenol"},{"key":"119_CR37","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1093\/ehjci\/jex340","volume":"19","author":"EC Wicks","year":"2018","unstructured":"Wicks EC, Menezes LJ, Barnes A, Mohiddin SA, Sekhri N, Porter JC et al (2018) Diagnostic accuracy and prognostic value of simultaneous hybrid 18F-fluorodeoxyglucose positron emission tomography\/magnetic resonance imaging in cardiac sarcoidosis. Eur Heart J Cardiovasc Imaging 19:757\u2013767","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"119_CR38","doi-asserted-by":"publisher","first-page":"W151","DOI":"10.2214\/AJR.07.2409","volume":"190","author":"G Williams","year":"2008","unstructured":"Williams G, Kolodny GM (2008) Suppression of myocardial 18F-FDG uptake by preparing patients with a high-fat, low-carbohydrate diet. Am J Roentgenol 190:W151\u2013W156","journal-title":"Am J Roentgenol"},{"key":"119_CR39","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2967\/jnumed.111.090662","volume":"53","author":"G Youssef","year":"2012","unstructured":"Youssef G, Leung E, Mylonas I, Nery P, Williams K, Wisenberg G et al (2012) The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med 53:241\u2013248","journal-title":"J Nucl Med"}],"container-title":["European Journal of Hybrid Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-021-00119-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s41824-021-00119-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s41824-021-00119-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T17:20:05Z","timestamp":1674062405000},"score":1,"resource":{"primary":{"URL":"https:\/\/ejhi.springeropen.com\/articles\/10.1186\/s41824-021-00119-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["119"],"URL":"https:\/\/doi.org\/10.1186\/s41824-021-00119-w","relation":{},"ISSN":["2510-3636"],"issn-type":[{"value":"2510-3636","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"18 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the hospital IRB, and written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent was obtained from all participants.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Author KH has received a speaker honorarium from Sanofi Genzyme, Amicus and Medscape.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"24"}}